What is Ripretinib?

Ripretinib is sold under the brand name Qinlock and is usually administered orally. RepetinibIt is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumors (GIST) who have previously received at least three kinase inhibitors, including imatinib (imatinib). GIST is a type of stomach, intestinal or esophageal tumor that originates in the gastrointestinal tract.

The approval of repetinib was based on the results of an international, multicenter, randomized, double-blind, placebo-controlled clinical trial in which participants received 150 mg once daily during a 28-day cycle. Repetinib or placebo was administered until tumor growth (disease progression) or participants experienced intolerable side effects. Other efficacy outcome measures included BICR overall response rate (ORR) and overall survival (OS). The trial demonstrated a statistically significant improvement in PFS for participants in the repetinib group compared with the placebo group.

The original drug of Ripetinib has been marketed in China and has been approved by the National Medical Insurance Bureau to enter the scope of Class B medical insurance, but it is limited to patients who meet the indications. The price of each box of 50mg*30 tablets may be around 30,000 yuan. The expensive price may increase the pressure on families with heavy financial burdens. The US version of Ripetinib Specifications50mg*90 tablets sold overseas may be priced around RMB 77,000 per box (the price may fluctuate due to exchange rates). The ingredients of foreign original drugs are basically the same as those of domestic original drugs. Currently, there is no generic drug of Ripetinib produced and marketed overseas. For specific prices and drug information, please consult Yaode’s medical consultant.